AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$HTFL

Rogers Campbell sold $987K of HTFL

Rogers Campbell (Chief Medical Officer) sold 19,682 shares of Heartflow, Inc. (HTFL) at $50.15 ($0.99M total) on 2026-09-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rogers Campbell
Published Sep 21, 2026, 10:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HTFL
Bearish
medium confidence
Mentioned
$HTFL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HTFLBearishLow
01

Why it matters

The insider sale provides fresh data on executive holdings, offering a modest trading signal.

02

Market read

New Form 4 filing reveals insider sell of ~$1M, a modest negative cue for HTFL.

03

What to watch

Pre-arranged 10b5-1 plan reduces signaling concerns; sale may be routine liquidity need.

Relevance 4/10Novelty 7/10Timing: filing date 2026-09-21

Background

Heartflow, Inc. (HTFL) develops non-invasive cardiac imaging technology. Recent insider activity is disclosed via SEC Form 4.

Company-level read

Ticker impact

$HTFLBearishMedium confidence
Context

Chief Medical Officer Rogers Campbell sold 19,682 shares for $987,052 via a 10b5-1 plan, reducing his stake to 79,956 shares.

Expected impact

Possible short-term dip as market digests insider sell.

Evidence & confidence

Sale size is under $1M but involves a senior executive; market may view as a modest negative signal.

Market effects

Sector

Minimal impact on the medical device/diagnostics sector.

Regional

Limited to US investors tracking HTFL.

Global

Low

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not reflect company fundamentals.

Key entities

  • Officer
    Rogers Campbell

    Chief Medical Officer of Heartflow, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HTFL insider trading history →

Related articles

SEP 13
$HTFLHigh

HTFL Soars After Q2 Beat And Raised 2026 Revenue Outlook

HeartFlow (HTFL) stock rose 9.63% after Q2 earnings beat and raised 2026 revenue outlook. Q2 revenue was $64.08M with 80.1% gross margin, but -55.8% profit margin. Company has strong liquidity with $162.55M cash and low debt. Analysts see near-term support at $46-$47 and resistance at $54-$56, with a 12-month target of $60 if growth continues.

timothysykes.com2 min
AUG 19
$HTFLMedAI 8/10

Why Heartflow Stock Soared Today

HeartFlow (HTFL) shares rose after the company raised its full-year revenue targets. Revenue grew 48% YoY to $64.1M in Q2, with adjusted gross margin increasing to 83.3%. The company now expects 40-42% revenue growth for 2026, up from prior forecasts. CEO John Farquhar cited improved operating leverage and scalability.

aol.com2 min